CCSD code M7020 – Transrectal prostate sextant needle biopsy

Key takeaways

CCSD Code M7020 covers a six-core (sextant) transrectal needle biopsy of the prostate under TRUS guidance, bundling the imaging and biopsy into one code.

Histopathology processing of the biopsy cores is not included in M7020 and is billed under a separate laboratory code.

The ICD-10 codes R97.2 (elevated PSA) and C61 (prostate cancer) are the most common medical necessity anchors paired with M7020.

Pre-authorisation requirements vary by UK private insurer and policy, so always verify with the patient’s insurer before the procedure date.

Pabau, the practice management platform we build, keeps procedure notes and patient records in one place, so M7020 claims go out fully documented.

CCSD Code M7020: Definition and clinical description

CCSD Code M7020 is defined by the CCSD coding schedule as “transrectal sextant needle biopsy of prostate with ultrasound guidance.” M7020 sits in chapter 12 of the schedule, alongside the other CCSD codes for the urinary system and male reproductive organs.

It is used only for the transrectal approach under real-time imaging. It is a bundled code, so a single claim covers both the TRUS component and the needle biopsy itself.

Two elements distinguish M7020 from other prostate biopsy codes. First, the route is transrectal. The biopsy needle passes through the rectal wall, guided by a transrectal ultrasound probe. Second, the sampling pattern is sextant, with six cores taken from the apex, mid-gland, and base on each side of the prostate.

Both characteristics must be present for M7020 to apply. Transperineal and MRI-guided biopsies take different codes, and an extended protocol needs the insurer’s ruling.

Private insurers including Bupa, AXA Health, Aviva, Vitality, WPA, Healix, and Allianz Care recognise M7020 within their CCSD-based fee schedules. Refer to the Bupa CCSD billing guide for Bupa-specific coding conventions that apply alongside M7020.

The procedure: Transrectal sextant needle biopsy step by step

M7020 covers the whole procedural sequence below, from preparation to discharge.

1. Patient preparation: The patient receives bowel preparation and prophylactic antibiotics. Consent is obtained and documented, including discussion of the risks of infection, haematuria, and haematospermia.
2. Probe insertion: A transrectal ultrasound probe is inserted into the rectum with the patient in the lateral decubitus or lithotomy position.
3. Ultrasound imaging: Real-time TRUS imaging visualises the prostate in both axial and sagittal planes. The urologist assesses gland volume, echotexture, and any suspicious hypoechoic lesions before sampling begins.
4. Sextant core sampling: A spring-loaded biopsy needle, guided by the ultrasound probe, takes six core samples bilaterally. The sites are right apex, right mid-gland, right base, left apex, left mid-gland and left base. Each core is typically 18 gauge, 20–22 mm in length.
5. Core handling: Each core is immediately placed in formalin-filled containers, labelled by site and laterality, and submitted for histopathological analysis under a separate laboratory code.
6. Post-procedure care: The patient is observed briefly, given written post-procedure instructions, and discharged. Complications such as haematuria are managed as they arise and coded separately if significant.

The ultrasound guidance in step 3 is an integral part of M7020. This distinguishes it from a “blind” transrectal biopsy performed without real-time imaging, which carries a different CCSD code.

When is M7020 performed? Clinical indications

M7020 is indicated when there is clinical suspicion of prostate cancer or a need to characterise prostatic pathology. The ICD-10 diagnosis paired with the claim must reflect one of these accepted indications.

• Elevated PSA (R97.2): A PSA value above the age-adjusted threshold, particularly a rising trend, is the most common trigger. Most UK private insurers require the PSA value and date to appear in the clinical justification.
• Abnormal digital rectal examination (DRE): An asymmetric, nodular, or hard prostate on DRE warrants tissue diagnosis even when PSA is within normal range.
• Suspicious lesion on imaging (R93.8): A hypoechoic lesion on a previous ultrasound or an indeterminate lesion on MRI may justify biopsy. M7020 applies when the transrectal sextant protocol is chosen as the sampling method.
• Prostate cancer screening in high-risk patients (Z12.5): A family history of prostate cancer or a BRCA2 mutation may warrant surveillance biopsy. Cover depends on the patient’s policy.
• Active surveillance re-biopsy: Patients already diagnosed with low-risk prostate cancer (C61) on surveillance protocols may require repeat sampling. Confirm with the insurer whether a repeat biopsy under M7020 requires a fresh pre-authorisation.

ICD-10 diagnosis codes to pair with M7020

Every M7020 claim must carry an ICD-10 diagnosis code that establishes medical necessity. The diagnosis must appear in the clinical notes before the procedure date. The table below lists the codes most commonly paired with M7020 in UK private billing.

Use the most specific diagnosis code supported by the clinical documentation. Payers may query a claim where R97.2 (elevated PSA) is used but no PSA value or date is recorded in the notes. Record the PSA figure and collection date in the clinical notes before submitting the claim.

On an active surveillance re-biopsy, C61 establishes medical necessity in place of the PSA code.

What M7020 covers and what it excludes

M7020 is a bundled code. Its fee covers both the transrectal ultrasound guidance and the needle biopsy in a single submission. Billing both components separately on the same claim date would constitute double-billing under CCSD unbundling rules.

Histopathology is the exclusion that trips up this code most often. When a practice assumes M7020 includes laboratory processing, the pathology work can go unbilled entirely. Confirm with your pathology partner that they submit the tissue analysis code on their own invoice, not yours.

Neighbouring CCSD prostate biopsy codes

Using the wrong code on a claim that clearly describes one procedure type is a common audit trigger. The choice depends on route, guidance modality, and sampling protocol, checked in the order shown below.

The MRI-guided fusion biopsy distinction matters most in specialist urology practices where both techniques are performed. The clinical notes must clearly state the guidance modality used. Notes that say “prostate biopsy performed” without specifying ultrasound versus MRI leave the coder unable to defend the code if audited.

Modifiers and add-on codes

M7020 may be billed alongside other codes where additional separately identifiable services are provided on the same date. Modifiers reduce the risk of claim rejection when multiple codes appear together.

• Anaesthesia code: Local anaesthetic infiltration is typically performed by the urologist and included in the procedure. If the patient requires conscious sedation administered by an anaesthetist, bill the applicable CCSD anaesthesia code on a separate anaesthetist’s claim. Check with the patient’s insurer whether conscious sedation for TRUS biopsy needs its own pre-authorisation.
• Assistant surgeon: CCSD rules generally restrict assistant surgeon billing to procedures of defined complexity. Check the insurer’s assistant rules before submitting an assistant claim alongside M7020.
• Bilateral modifier: M7020 is by definition a bilateral procedure (bilateral sampling is inherent in the sextant protocol). Insurers will not accept a bilateral claim on top of M7020.
• Consultation code: A pre-operative consultation on the same day as the procedure is excluded by most insurers. If the consultation occurs on a separate date, bill it normally.
• PSA or DRE on the same date: Some insurers allow an office investigation code for a PSA blood test or DRE at the same visit. Others bundle these into the consultation fee. Verify against each insurer’s rules.

When in doubt, call the insurer’s provider line before submitting to confirm which ancillary codes they accept alongside M7020. Undisclosed add-on codes that surface at claims review are a common reason for retrospective clawbacks.

Pre-authorisation for prostate biopsy billing

Most UK private insurers, including Bupa, AXA Health, Aviva and Vitality, require pre-authorisation for surgical or invasive procedures. Whether pre-auth is mandatory for M7020 depends on the insurer and the patient’s policy. There is no universal rule across all payers.

Treat pre-auth as required unless the insurer confirms in writing that it is not needed for this procedure under this patient’s policy.

When applying for pre-authorisation, include the following in every application.

• Patient’s policy or membership number, insurer name, and level of cover
• Treating urologist’s insurer provider or recognition number and billing details
• Proposed CCSD code (M7020) and planned procedure date
• Primary ICD-10 diagnosis code and clinical justification (PSA value with date, DRE findings, or imaging report summary)
• Hospital or facility where the procedure will be performed
• Any co-morbidities relevant to the risk profile

When pre-auth is omitted and a claim is subsequently submitted, most UK insurers will reject the claim outright. The patient may then be left to pay for the procedure themselves. Appeals are possible but time-consuming. Obtaining authorisation before the procedure date is always faster than pursuing a retrospective appeal.

Documentation requirements for an M7020 claim

Inadequate clinical notes are the second most common cause of M7020 claim denials after missing pre-authorisation. The documentation must demonstrate medical necessity before the procedure, describe the procedure in sufficient clinical detail, and confirm the histopathology submission pathway.

Every M7020 claim should be supported by clinical notes that contain each of the elements below.

• Clinical indication documented before the procedure: PSA value with date, DRE findings, or imaging report reference. The payer must be able to see that the decision to biopsy was clinically justified on the date it was made.
• Ultrasound report or inline reference: Notes must confirm that TRUS guidance was used. A brief phrase (“procedure performed under real-time transrectal ultrasound guidance”) is sufficient if a formal imaging report is not generated.
• Number of cores taken and site labelling: Record all six sites (right apex, right mid, right base, left apex, left mid, left base). If fewer than six cores were obtained (e.g. due to technical difficulty), document why.
• Laterality: Bilateral sampling must be explicit. Notes that say “biopsy cores taken” without laterality cannot confirm the sextant protocol.
• Pathology submission reference: Record the laboratory name, the number of containers submitted, and the requisition or reference number. This confirms the cores were processed and closes the clinical episode.
• Operator details: Attending urologist’s name and signature, with date and time of the procedure.
• Consent note: Confirm that written informed consent was obtained and that risks (infection, haematuria, haematospermia) were discussed.

Pabau, the practice management platform we build, lets urology practices turn this list into a templated digital procedure note. The same fields are then captured for every patient, whichever urologist performs the biopsy.

Keep the pre-operative consultation, the procedure note, and the pathology result together in a single patient file. When an insurer requests clinical records during an audit, producing the complete episode in one place cuts the time to resolve the claim.

Common denial reasons and how to fix them

Most M7020 rejections are preventable. The table below maps the most frequent denial patterns to their root cause and the corrective action needed before resubmission.

Practices using claims management software can automate the pre-submission check. It flags missing pre-auth numbers, mismatched ICD-10 codes, and incomplete documentation fields before the claim reaches the payer. Catching errors at submission is faster and cheaper than handling denials after the fact.

Coding post-biopsy complications

Complications after a TRUS-guided prostate biopsy are recognised in urology literature and require separate coding when they result in an additional clinical encounter or intervention.

The three most common complications and their coding rules for follow-up care are listed below.

• Haematuria (R31.9): Transient haematuria is expected after TRUS biopsy and usually resolves within 48 hours. It does not trigger a separate procedure code unless it is persistent or requires cystoscopic evaluation. If the patient returns with haematuria that does not resolve on its own, bill that consultation with R31.9 as the primary ICD-10 code, not M7020.
• Post-procedural infection or sepsis (T81.4): Post-biopsy sepsis is a recognised risk, particularly with fluoroquinolone-resistant organisms. If the patient is admitted or returns for intravenous antibiotics, bill the admission and treatment under the applicable inpatient codes. T81.4 (infection following a procedure) is the appropriate ICD-10 code. M7020 is not rebilled for the complication management.
• Haematospermia (R36.1): Blood in semen after biopsy is expected and rarely requires intervention. If the patient presents with anxiety or persistent haematospermia requiring reassurance consultation, bill the consultation with R36.1. It is not a complication that justifies billing an additional procedure code.

When a complication requires a second procedure in the same hospital admission, bill M7020 on the original procedure date. Bill the second procedure code on the date it was performed.

Never merge both procedures under a single M7020 claim. Each procedure date must have its own claim line and its own clinical documentation.

How Pabau keeps M7020 claims complete before submission

The evidence an M7020 claim depends on is often scattered. The PSA result sits in a lab portal, the consent form on paper, and the pre-authorisation number in an inbox.

In Pabau, consent forms, procedure notes, and pre-authorisation references are stored against the same patient record. Its Healthcode integration then sends the CCSD claim electronically to UK private insurers.

Your team stops chasing missing details after a rejection, and an audit request is answered from one patient file.

Manage CCSD billing and clinical records in one place

Pabau keeps procedure notes, consent forms, and claim documentation linked to each patient file. Pre-authorisation requests and audit responses become faster and more complete.

Book a demo

Conclusion

M7020 is one of the easier CCSD codes to get right, because its descriptor leaves little room for interpretation. If the biopsy was transrectal, ultrasound-guided and six-core, the code fits.

When an M7020 claim fails, the cause almost always sits outside the procedure. Build the pre-authorisation check into scheduling, and make every procedure note record core count, laterality and the pathology reference. The risk left after that is an insurer-specific rule, which one call to the provider line settles.

Book a demo to see how Pabau links consent, procedure notes and Healthcode claims for your urology patients.

Continue your research

Comparing billing software for a UK private practice? Best medical billing software in the UK reviews the leading platforms for CCSD coding, Healthcode claim submission, and insurer billing.

Want to reduce claim rejections across all procedure codes? Pabau’s claims management software connects clinical notes to billing codes and flags missing documentation before a claim is submitted.

Pricing an M7020 claim for Bupa? Bupa procedure codes fee schedule lists Bupa’s procedure codes with their fee schedule links, so you can check the M7020 fee before you quote.

Frequently asked questions about CCSD Code M7020